Who are Clotrimazole vaginal tablets+ Lactobacillus's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clotrimazole-vaginal-tablets-lactobacillus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Clotrimazole vaginal tablets+ Lactobacillus — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clotrimazole vaginal tablets+ Lactobacillus (Clotrimazole vaginal tablets+ Lactobacillus) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifungal + probiotic combination. Area: Gynecology / Infectious Disease.

marketed Antifungal + probiotic combination Fungal lanosterol 14α-demethylase (CYP51); Lactobacillus competitive exclusion and microbiota restoration Gynecology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Clotrimazole vaginal tablets+ Lactobacillus (Clotrimazole vaginal tablets+ Lactobacillus) — Peking University Shenzhen Hospital. Clotrimazole kills vaginal fungi while Lactobacillus restores healthy vaginal microbiota to treat and prevent vaginal yeast infections.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clotrimazole vaginal tablets+ Lactobacillus TARGET	Clotrimazole vaginal tablets+ Lactobacillus	Peking University Shenzhen Hospital	marketed	Antifungal + probiotic combination	Fungal lanosterol 14α-demethylase (CYP51); Lactobacillus competitive exclusion and microbiota restoration

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifungal + probiotic combination class)

Peking University Shenzhen Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clotrimazole vaginal tablets+ Lactobacillus — Competitive Intelligence Brief. https://druglandscape.com/ci/clotrimazole-vaginal-tablets-lactobacillus. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab